Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BKK:AMARC's EV-to-EBITDA is ranked better than 74.62% of 1911
companies
in the Hardware industry
Industry Median: 14.11
vs BKK:AMARC: 6.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Asia Medical and Agricultural Laboratory and Research Center PCL's PE Ratio (TTM) for today is calculated as:
Asia Medical and Agricultural Laboratory and Research Center PCL's share price for today is ฿3.18.
Asia Medical and Agricultural Laboratory and Research Center PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.304.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Medical and Agricultural Laboratory and Research Center PCL EV-to-EBITDA Chart
Asia Medical and Agricultural Laboratory and Research Center PCL Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asia Medical and Agricultural Laboratory and Research Center PCL EV-to-EBITDA vs Hardware Industry
Asia Medical and Agricultural Laboratory and Research Center PCL's current Enterprise Value is ฿1,171.8 Mil.
Asia Medical and Agricultural Laboratory and Research Center PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿167.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) has a EV-to-EBITDA of 6.99 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL. This is 15% below median its historical median of 8.23. Over the past decade, Asia Medical and Agricultural Laboratory and Research Center PCL's EV-to-EBITDA has ranged from 3.90 to 28.33. According to the industry distribution chart, Asia Medical and Agricultural Laboratory and Research Center PCL ranks #485 out of 1911 companies in the Hardware industry, placing it in the top 25.4%.
Is Asia Medical and Agricultural Laboratory and Research Center PCL's EV-to-EBITDA too high?
Asia Medical and Agricultural Laboratory and Research Center PCL's current EV-to-EBITDA of 6.99 is 15% below median its 10-year median of 8.23. Over the past 10 years, this metric has ranged from a low of 3.90 to a high of 28.33. The Hardware industry median EV-to-EBITDA is 14.11. Asia Medical and Agricultural Laboratory and Research Center PCL's value of 6.99 is 50.5% below this industry median. Based on the distribution chart, Asia Medical and Agricultural Laboratory and Research Center PCL ranks #485 out of 1911 companies in the Hardware industry, which is above the industry midpoint. Overall, Asia Medical and Agricultural Laboratory and Research Center PCL has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asia Medical and Agricultural Laboratory and Research Center PCL's EV-to-EBITDA compare to COHR and KEYS?
According to the Hardware industry distribution chart, Asia Medical and Agricultural Laboratory and Research Center PCL ranks #485 out of 1911 companies for EV-to-EBITDA. This puts Asia Medical and Agricultural Laboratory and Research Center PCL in the upper half of its industry. The industry median EV-to-EBITDA is 14.11. Asia Medical and Agricultural Laboratory and Research Center PCL's value of 6.99 is 50.5% below this benchmark. Historically, Asia Medical and Agricultural Laboratory and Research Center PCL's own EV-to-EBITDA has ranged from 3.90 to 28.33 over the past decade. While the company's 10-year median is 8.23 vs. the industry median of 14.11, Asia Medical and Agricultural Laboratory and Research Center PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Hardware company?
The median EV-to-EBITDA among Hardware companies is 14.11, based on 1,911 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asia Medical and Agricultural Laboratory and Research Center PCL's current EV-to-EBITDA of 6.99 is 50.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Asia Medical and Agricultural Laboratory and Research Center PCL. For the Hardware industry, the median EV-to-EBITDA is 14.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asia Medical and Agricultural Laboratory and Research Center PCL's current EV-to-EBITDA is 6.99, which is 15% below median its own 10-year median of 8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asia Medical and Agricultural Laboratory and Research Center PCL stock overvalued right now?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) is currently considered Significantly Overvalued. The stock's GF Value™ is ฿2.36, compared to a current price of ฿3.18 — trading 34.7% above its estimated fair value. The current EV-to-EBITDA is 6.99, which is 15% below median its 10-year median of 8.23 and 50.5% below the Hardware industry median of 14.11. Asia Medical and Agricultural Laboratory and Research Center PCL's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC), the current EV-to-EBITDA is 6.99 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asia Medical and Agricultural Laboratory and Research Center PCL (BKK:AMARC) Overvalued in 2026?
Based on GuruFocus' analysis, Asia Medical and Agricultural Laboratory and Research Center PCL stock appears to be overvalued.
The current stock price of ฿3.18 is trading 34.7% above its estimated GF Value™ of ฿2.36.
GuruFocus considers Asia Medical and Agricultural Laboratory and Research Center PCL to be Significantly Overvalued.
Key valuation signals for BKK:AMARC:
EV-to-EBITDA: 6.99 (15% below median its 10-year median of 8.23)
GF Value™: ฿2.36 vs. price of ฿3.18 (34.7% above fair value)
Industry Position: 50.5% below the Hardware median (#485 of 1911)
No single metric tells the full story. See the BKK:AMARC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asia Medical and Agricultural Laboratory and Research Center PCL is engaged in providing comprehensive scientific services for the agriculture, food, pharmaceutical and environment sectors including testing, calibration, inspection and certification according to international quality standards. The company geographically operates only in Thailand.
82GF Score
Get the complete analysis for BKK:AMARC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:AMARC has been successfully added to your 
